antibody | Antibody | Anti-neutrophil cytoplasmic antibody | Nomenclature of monoclonal antibodies | Single-domain antibody | Humanized antibody | Anti-nuclear antibody | Anti-glomerular basement membrane antibody | Anti-citrullinated protein antibody | Antibody therapy | Antibody-drug conjugate | antibody-dependent cell-mediated cytotoxicity |
Lebrikizumab (INN) is a humanized monoclonal antibody and an experimental immunosuppresive drug for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids.
Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer.
Lampalizumab (INN) is a humanized monoclonal antibody designed for the treatment of geographic atrophy secondary to age-related macular degeneration.
Ligelizumab (INN) is a humanized monoclonal antibody that binds to IGHE.
Parsatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer.
Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis.
Quilizumab (INN) is a humanized monoclonal antibody designed for the treatment of asthma.
Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis.